Janux Therapeutics, Inc. Current Assets
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
| Current Assets | $658.0K | $16.1M | $377.0M | $332.4M | $349.2M | $1,033.7M |
Janux Therapeutics, Inc. (JANX) Current Assets comparison analysis
General
LTM Current Assets
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
JANX key stats
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 3.6 0.0% | 8.6 136.8% | 8.1 (6.1%) | 10.6 31.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.1 | 0.8 | 2.0 | 0.0 |
% margin | (0.0) 0.0% | (0.0) 0.0% | 3.5 96.9% | 7.8 90.2% | 6.1 75.8% | 10.6 100.0% |
| Operating Expenses | 3.8 | 4.8 | 36.6 | 75.7 | 81.1 | 109.4 |
| Research & Development Expenses (R&D) | 3.0 | 3.0 | 26.2 | 53.4 | 54.9 | 68.4 |
| Selling, General & Administrative Expenses (SG&A) | 0.8 | 1.8 | 10.3 | 22.3 | 26.1 | 41.0 |
% margin | (3.8) 0.0% | (4.8) 0.0% | (32.9) (905.4%) | (67.1) (779.0%) | (73.0) (902.9%) | (98.8) (933.6%) |
| Interest Income | 0.2 | 0.2 | 0.3 | 4.0 | 14.7 | 29.9 |
| Interest Expense | 0.2 | 0.2 | 0.0 | 4.0 | 0.0 | 0.0 |
| Pre-tax Income | (4.0) | (6.8) | (32.7) | (63.1) | (58.3) | (69.0) |
% effective tax rate | 0.2 (5.8%) | (1.5) 22.5% | (0.1) 0.3% | (8.9) 14.1% | 0.0 0.0% | 0.0 0.0% |
% margin | (4.2) 0.0% | (5.3) 0.0% | (32.6) (895.2%) | (54.2) (628.8%) | (58.3) (721.2%) | (69.0) (651.6%) |
| EPS | (0.10) | (0.13) | (0.79) | (1.31) | (1.32) | (1.28) |
| Diluted EPS | (0.10) | (0.13) | (0.79) | (1.31) | (1.32) | (1.28) |
% margin | (3.8) 0.0% | (4.8) 0.0% | (32.8) (902.3%) | (66.3) (769.3%) | (71.0) (878.7%) | (98.8) (933.6%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Janux Therapeutics, Inc.'s Current Assets?
As of today, Janux Therapeutics, Inc.'s last 12-month Current Assets is $1,033.7M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Janux Therapeutics, Inc.'s Current Assets growth rate?
Over the last year, Janux Therapeutics, Inc.'s Current Assets growth was 196.0%. The average annual Current Assets growth rates for Janux Therapeutics, Inc. have been 37.6% over the past three years, 335.7% over the past five years.
3) Is Janux Therapeutics, Inc.'s Current Assets growth rate Good?
Over the last year, Janux Therapeutics, Inc.'s Current Assets growth was 196.0%, which is higher than industry growth of (0.1%). It indicates that Janux Therapeutics, Inc.'s Current Assets growth is Good.